Amgen Invests $66 Million In Oxford Nanopore Technologies

24-Oct-2018 - Amgen and Oxford Nanopore Technologies Ltd. announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. Oxford Nanopore has developed and brought to market ...

Amgen and European Schoolnet Launch New Professional Development Initiative for Life Science Teachers

Program Will Help Increase Student Interest and Achievements in Science in France, Germany, Ireland and Poland

01-Mar-2012 - The Amgen Foundation and European Schoolnet launched the "Amgen Science Teacher Training Initiative" in France, Germany, Ireland and Poland.The Amgen Science Teacher Training Initiative provides professional development for secondary school science teachers to help them incorporate hands-on ...

Galapagos extends drug discovery collaboration with Amgen into 2010

22-Dec-2008 - Galapagos NV announced that its service division BioFocus DPI has extended its longstanding drug discovery collaboration with Amgen through 2009 and 2010. BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply small molecule compounds for ...

Galapagos expands and extends drug discovery collaboration with Amgen into 2008

04-Jan-2007 - Galapagos NV announced that its service division BioFocus DPI has expanded and extended its longstanding drug discovery collaboration with Amgen through 2007 and 2008. BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply ...

Amgen Names Yuji Orihara President, Amgen KK

05-Dec-2006 - Amgen announced the appointment of Yuji Orihara to the position of president and representative director, Amgen KK, effective immediately. Amgen KK was formed in 1992 in Japan as a wholly owned subsidiary of Amgen Inc. Orihara will be responsible for all aspects of Amgen's commercial efforts in ...

Galapagos extends its collaboration with Amgen throughout 2006

08-Dec-2005 - Galapagos announced that its services division BioFocus has extended its drug discovery collaboration with Amgen for biology, computational/medicinal chemistry services and supply of biologically-directed library compounds for Amgen's ion channel lead discovery programs throughout 2006. This ...

Amgen Strengthens Focus on Oncology Pipeline

Amgen Names David R. Parkinson to New Role in Research and Development Organization

08-Aug-2005 - Amgen announced that David R. Parkinson, M.D., formerly vice president and head of Global Clinical Oncology, will assume a new role as vice president, Oncology Development and Commercialization. In this new position, Parkinson will join Amgen's most senior executives as a member of the Pipeline ...

Gene therapy for Parkinson's Disease moves forward in animals

11-Feb-2005 - An international team of scientists has used gene therapy in two separate studies to renew brain cells and restore normal movements in monkeys and rats with a drug-induced form of Parkinson's disease. The research, detailed online in the scientific publications Brain and The Journal of ...

Amgen Opens State-of-the-Art Biotechnology Research Campus

40-Acre Seattle Campus Focuses on Advancing Cancer and Immunology Therapies

26-Feb-2004 - Seattle. Amgen Inc., the world's largest biotechnology company, announced the official opening of its new state-of-the-art research and development campus. The 750,000 square foot facility was designed in collaboration with scientists as an environment for the creation of breakthrough therapies. ...